Referral Recommendation for Multiple Pancreatic and Renal Cysts

Pancreatic Cyst Management Priority

The American Gastroenterological Association recommends EUS-FNA for pancreatic cysts approaching 3 cm, as the risk of malignancy increases approximately 3-fold at this size, in patients with pancreatic cysts measuring 2.7 cm, such as the one described 1, 2
Cysts measuring ≥3 cm are classified as "worrisome features" and require tissue diagnosis to distinguish between benign pseudocysts and potentially neoplastic mucinous lesions, according to the American College of Radiology and Gut guidelines, for patients with pancreatic cysts 3, 4, 1
The location of the cyst in the pancreatic body increases concern, as body/tail lesions may represent mucinous cystic neoplasms which have malignant potential, as noted by the Nature Reviews Gastroenterology and Hepatology 5
EUS-FNA should include cyst fluid analysis for cytology examination, carcinoembryonic antigen (CEA) level, and DNA analysis for KRAS mutations, as recommended by the American Gastroenterological Association, for patients undergoing EUS-FNA for pancreatic cysts 1, 2
Prior to EUS-FNA, dedicated pancreatic MRI with MRCP should be performed to establish baseline characteristics and detect additional worrisome features, according to the Journal of the American College of Radiology, for patients with pancreatic cysts 6, 3, 7

The American Urological Association recommends urologic evaluation for renal cysts larger than 4 cm, such as the 7 cm left renal cyst, to exclude complex features or Bosniak classification that would indicate malignancy risk, for patients with renal cysts 1
Dedicated renal imaging (contrast-enhanced CT or MRI) should be performed to characterize cyst complexity using the Bosniak classification system, as recommended by the Journal of the American College of Radiology, for patients with renal cysts 3
Simple cysts (Bosniak I-II) require no follow-up, while complex cysts (Bosniak III-IV) may require surgical intervention or surveillance, according to the Gut guidelines, for patients with renal cysts 4

If EUS-FNA confirms a benign lesion, MRI surveillance at 1 year, then every 2 years for a total of 5 years if stable, is recommended by the American Gastroenterological Association, for patients with benign pancreatic cysts 1, 2
If EUS-FNA suggests a mucinous or potentially malignant lesion, surgical evaluation is required, especially given the cyst's size, as recommended by the American Gastroenterological Association, for patients with mucinous or potentially malignant pancreatic cysts 1
If high-risk stigmata develop, direct surgical referral without intermediate steps is recommended by the Journal of the American College of Radiology and Gut guidelines, for patients with high-risk pancreatic cysts 3, 4, 8

Delaying pancreatic cyst evaluation can result in missed dysplasia or early malignancy, as noted by the American Gastroenterological Association, for patients with pancreatic cysts approaching 3 cm 1, 2
Assuming the pancreatic cyst is a pseudocyst without tissue diagnosis can lead to incorrect management, as recommended by the Journal of the American College of Radiology, for patients with pancreatic cysts 3
Performing surveillance imaging without baseline EUS-FNA at this size is not recommended by the American Gastroenterological Association, for patients with pancreatic cysts approaching 3 cm 1
Ignoring the large renal cyst can lead to delayed diagnosis of malignancy, as recommended by the American Urological Association, for patients with large renal cysts 1

Gastroenterology referral should be expedited (within 2-4 weeks) given the pancreatic cyst size and malignancy risk, as recommended by the American Gastroenterological Association, for patients with pancreatic cysts approaching 3 cm 1, 2
Urology referral can be routine (within 4-8 weeks) unless imaging suggests complex features requiring urgent evaluation, as recommended by the American Urological Association, for patients with renal cysts 1